Bridger Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bridger Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.1M	Hold	367,600	–	–	8.65%	3
2025 Q4	$11.5M	Sell	367,600 -327,400	-47%	-$8.07M	7.38%	3
2025 Q3	$14M	Hold	695,000	–	–	7.56%	3
2025 Q2	$11.6M	Hold	695,000	–	–	6.87%	4
2025 Q1	$10.7M	Hold	695,000	–	–	5.31%	6
2024 Q4	$15.3M	Sell	695,000 -286,000	-29%	-$5.2M	8.23%	4
2024 Q3	$17.7M	Hold	981,000	–	–	8.84%	4
2024 Q2	$15.9M	Sell	981,000 -519,000	-35%	-$7.99M	8.2%	5
2024 Q1	$21.2M	Hold	1,500,000	–	–	9.54%	3
2023 Q4	$15.7M	Hold	1,500,000	–	–	6%	7
2023 Q3	$15.3M	Hold	1,500,000	–	–	5.61%	6
2023 Q2	$11.3M	Hold	1,500,000	–	–	3.75%	13
2023 Q1	$13.3M	Hold	1,500,000	–	–	4.94%	10
2022 Q4	$13.7M	Hold	1,500,000	–	–	5.53%	8
2022 Q3	$12.1M	Hold	1,500,000	–	–	3.66%	8
2022 Q2	$11.3M	Hold	1,500,000	–	–	2.54%	17
2022 Q1	$14.1M	Hold	1,500,000	–	–	2.31%	16
2021 Q4	$12M	Hold	1,500,000	–	–	1.55%	25
2021 Q3	$14.6M	Hold	1,500,000	–	–	1.71%	21
2021 Q2	$14.8M	Hold	1,500,000	–	–	1.39%	25
2021 Q1	$17.3M	Hold	1,500,000	–	–	1.62%	25
2020 Q4	$14.5M	Hold	1,500,000	–	–	1.1%	25
2020 Q3	$13.5M	Hold	1,500,000	–	–	1.08%	28
2020 Q2	$18.5M	Hold	1,500,000	–	–	1.71%	24
2020 Q1	$13.5M	Hold	1,500,000	–	–	1.56%	26
2019 Q4	$14.7M	Hold	1,500,000	–	–	1.06%	30
2019 Q3	$10.3M	Hold	1,500,000	–	–	0.85%	29
2019 Q2	$13.8M	Hold	1,500,000	–	–	1.09%	29
2019 Q1	$23.5M	Hold	1,500,000	–	–	1.86%	24
2018 Q4	$23.1M	Hold	1,500,000	–	–	1.93%	22
2018 Q3	$32.3M	Hold	1,500,000	–	–	1.87%	23
2018 Q2	$36.5M	Buy	1,500,000 +750,000	+100%	+$15.3M	1.98%	24
2018 Q1	$12.8M	Hold	750,000	–	–	0.78%	32
2017 Q4	$14.2M	Hold	750,000	–	–	0.94%	29
2017 Q3	$13.2M	Hold	750,000	–	–	0.79%	32
2017 Q2	$24.9M	Sell	750,000 -1,088,440	-59%	-$33.7M	1.42%	31
2017 Q1	$59M	Buy	+1,838,440	New	+$62.7M	3.37%	10
2016 Q4	–	Sell	-1,358,287	Closed	-$62.5M	–	45
2016 Q3	$62.5M	Buy	1,358,287 +53,715	+4%	+$2.8M	4.21%	7
2016 Q2	$65.5M	Buy	1,304,572 +195,998	+18%	+$10.4M	4.23%	8
2016 Q1	$59.3M	Sell	1,108,574 -773,263	-41%	-$45.4M	4.1%	7
2015 Q4	$124M	Sell	1,881,837 -22,509	-1%	-$1.39M	4.08%	2
2015 Q3	$108M	Buy	+1,904,346	New	+$123M	7.33%	1
2015 Q2	–	Sell	-406,756	Closed	-$25.3M	–	49
2015 Q1	$25.3M	Sell	406,756 -1,078,244	-73%	-$62.7M	1.69%	25
2014 Q4	$85.4M	Buy	1,485,000 +271,638	+22%	+$15.1M	5.38%	2
2014 Q3	$65.2M	Buy	1,213,362 +460,862	+61%	+$24.4M	4.44%	4
2014 Q2	$39.4M	Sell	752,500 -262,500	-26%	-$13.4M	2.78%	18
2014 Q1	$53.6M	Buy	1,015,000 +100,000	+11%	+$4.62M	3.58%	9
2013 Q4	$36.7M	Buy	915,000 +75,000	+9%	+$2.95M	2.56%	21
2013 Q3	$31.7M	Buy	840,000 +105,000	+14%	+$4.1M	2.27%	24
2013 Q2	$28.8M	Buy	+735,000	New	+$28.6M	2.12%	27

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridger Management's TEVA Position: Q1 2026 in Review

Bridger Management held its Teva Pharmaceuticals (TEVA) position steady in Q1 2026 at 367,600 shares worth $11.1M. The position accounts for 8.65% of the portfolio, ranked #3.

Bridger Management first reported a position in TEVA in Q2 2013 and has held it in 50 quarters since. The position peaked at $124M in Q4 2015. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Bridger Management held 367,600 shares of Teva Pharmaceuticals worth $11.1M as of Q1 2026.
Bridger Management left its Teva Pharmaceuticals share count unchanged in Q1 2026.
Teva Pharmaceuticals made up 8.65% of Bridger Management's portfolio in Q1 2026, its #3 holding.
Bridger Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
Bridger Management's Teva Pharmaceuticals position peaked at $124M in Q4 2015.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Bridger Management's 13F filing for Q1 2026, filed 15 May 2026.